Keyphrases
Disseminated Tumor Cells
75%
Pluripotency
75%
Quiescence
75%
Dormancy
54%
NR2F1
40%
Nanog
27%
Sex-determining Region Y-box 2 (SOX2)
27%
Residual Disease
20%
Dormant
20%
Tumor Cell Dormancy
20%
Dormant Cells
13%
Metastasis
13%
Primary Tumor
13%
Retinoids
13%
Genomic Landscape
13%
Bone Marrow Aspirate
13%
Mouse Model
13%
Metastasis Risk
9%
Reduced Survival
6%
Clinical Trials
6%
Overexpression
6%
Molecular Markers
6%
Hijack
6%
Tet-on
6%
Immunofluorescence
6%
Life-threatening
6%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
6%
Response to Therapy
6%
Metastatic Dormancy
6%
Computational Approach
6%
Tumor-initiating
6%
Tumor Relapse
6%
Responsive Genes
6%
Patients at Risk
6%
Metastasis Formation
6%
Gene Transcription
6%
Histone Post-translational Modifications
6%
Stem Cell Genes
6%
Post-translational Modification
6%
Sequence Method
6%
Therapeutic Agents
6%
Pluripotency Genes
6%
Complementary DNA (cDNA)
6%
Loss-of-function Experiments
6%
Chromatin Immunoprecipitation (ChIP)
6%
Specific Intent
6%
Potential Therapeutics
6%
DNA Methyltransferase Inhibitor
6%
Remission
6%
Human Samples
6%
Dormancy Phase
6%
Response Monitoring
6%
Re-expression
6%
Stem Cells
6%
Gain-of-function
6%
Immunochemistry
6%
Minimal Residual Disease
6%
Therapeutic Potential
6%
Surgical Removal
6%
High-risk of Recurrence
6%
Pharmacology, Toxicology and Pharmaceutical Science
Metastasis
100%
Neoplasm
33%
Minimal Residual Disease
33%
Retinoid
16%
Primary Tumor
16%
Malignant Neoplasm
16%
Mouse Model
16%
Remission
8%
Disease
8%
Head and Neck Carcinoma
8%
Molecular Marker
8%
Histone H3
8%
Complementary DNA
8%
Recurrent Disease
8%
Clinical Trial
8%
Biochemistry, Genetics and Molecular Biology
Dormancy
100%
SOX2
30%
Posttranslational Modification
15%
Mouse Model
15%
Epigenomics
15%
Stem Cell
15%
Retinoid
15%
ChIP-sequencing
7%
Genetic Transcription
7%
Cancer Cell
7%
Clinical Trial
7%
DNA Methylation
7%
Genetic Marker
7%
Histone H3
7%
Immunofluorescence
7%
Reprogramming
7%